The NEOCANTAL project aims to obtain dietary supplements very rich in a specific phenolic compound called Oleocantal from olives.

Work is underway to offer the NEOCANTAL product in three different formats:

Powder – Oleocantal richness up to 30,000 mg/kg (use: food additive)
Liquid – Oleocantal richness up to 50,000 mg/kg (use: food additive and cosmetic industry)
Encapsulated – Oleocantal richness up to 80,000 mg/kg (use: nutraceutical supplement, providing maximum Oleocantal bioavailability).

Clinical trials carried out by various scientists have highlighted the anti-inflammatory and antioxidant properties of the oleocanthal molecule. This exceptional compound is synthesized mainly in the few olive tree cultivars identified by SCI. Thus, oleocantal is present in both olives and extra virgin olive oil (EVOO), although in lower concentrations.

Scientist Beauchamp, along with his collaborators, identified the anti-inflammatory effect of oleocantal and its similarities to ibuprofen, noting that this compound could combat various diseases related to chronic inflammation, such as arthritis, rheumatoid arthritis, and Alzheimer’s, among others. The scientist recommends daily and continuous long-term consumption of 50 g of EVOO with a minimum oleocantal concentration of 200 mg/kg (equivalent to 9 mg/day/person). However, it is important to note that this dose corresponds to only 10% of the recommended ibuprofen dose for pain relief in an adult.

Ingesting more than 50 g of EVOO per day would be impossible because it would harm a person’s balanced diet. The World Health Organization and Dietary Intake References suggest that you should only obtain between 20% and 35% of total calories from fat sources.

Furthermore, in 2011, the European Food Safety Authority considered that daily consumption of 5 mg of phenols from EVOO, contributes to the antioxidant protection of lipids in the blood. Numerous clinical trials have demonstrated the positive effects against degenerative diseases (Alzheimer’s), cardiovascular diseases, and cancerous diseases, among others (Lopez-Huertas & Fonolla, 2017; Parkinson & Cicerale, 2016; Qosa et al., 2015; Rallo et al., 2018).